Viking Therapeutics is a clinical-stage biopharmaceutical company developing therapies for metabolic and endocrine disorders, including obesity and liver disease.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Steve Cohen / Point72 | 75 | New buy | 7,750,000 | $7,864,699 | 0.0% |
| Louis Bacon / Moore | 52 | New buy | 67,549 | $2,202,097 | 0.0% |
| Paul Tudor Jones / Tudor | 61 | Added +13% | 324,642 | $10,583,329 | 0.0% |
| Ancora | 42 | Holds (flat) | 570 | $18,582 | 0.0% |
| Steve Cohen / Point72 | 75 | Trimmed -69% | 155,216 | $5,060,042 | 0.0% |
| Bridgewater | 55 | Trimmed -5% | 83,172 | $2,711,407 | 0.0% |
| Report | Date | Stance |
|---|---|---|
| #134 — Citrini Therapeutics: We Wanted to Use Claude to Create a New Drug | 2026-10-20 | WATCH |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.